A Randomized Phase II Trial of Atezolizumab with or without Bevacizumab in Cisplatin-ineligible Patients with Advanced/Unresectable Urothelial Cancer
Brief description of study
If you have been diagnosed with urothelial or transitional cell cancer that cannot be operated on or has spread and you are not a candidate for cisplatin chemotherapy, you may qualify for this study. Atezolizumab is a standard treatment for patients who are not candidates for cisplatin and the main goal of this phase II study is to test whether adding bevacizumab to atezolizumab improves outcomes compared to atezolizumab alone.
Clinical Study Identifier: s16-01918
ClinicalTrials.gov Identifier: NCT03272217
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
